Advanced Oncotherapy PLC Director Dealing (6372S)

TIDMAVO

RNS Number : 6372S

Advanced Oncotherapy PLC

22 December 2016

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Enrico Vanni, a Non-Executive Director of the Company, purchased 25,000 ordinary shares of 25 pence each in the Company ("Ordinary Shares") at a price of 59.75 pence per Ordinary Share.

Following this transaction, Dr Vanni now holds 773,946 Ordinary Shares representing 1.07% of the issued share capital of the Company.

 
  Advanced Oncotherapy Plc                                       www.avoplc.com 
  Dr. Michael Sinclair, Executive                         Tel: +44 20 3617 8728 
   Chairman 
  Nicolas Serandour, CEO 
 
  Stockdale Securities (Nomad & 
   Joint Broker) 
  Antonio Bossi / David Coaten                            Tel: +44 20 7601 6100 
 
  Stifel Nicolaus Europe (Joint 
   Broker) 
  Jonathan Senior / Ben Maddison                          Tel: +44 20 7710 7600 
 
  Walbrook PR (Financial PR & IR)   Tel: +44 20 7933 8780 or avo@walbrookpr.com 
  Paul McManus / Anna Dunphy                   Mob: +44 7980 541 893 / Mob: +44 
                                                                   7876 741 001

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBXBDDUXDBGLD

(END) Dow Jones Newswires

December 22, 2016 08:36 ET (13:36 GMT)

Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2024 to May 2024